Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.

Slides:



Advertisements
Similar presentations
Care Coordinator Roles and Responsibilities
Advertisements

Adverse Event Reporting: Getting started Lynn Bahta, R.N., B.S.N Minnesota Department of Health August 2008.
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.
Julianne Gee, MPH Immunization Safety Office
VACCINE SAFETY: 101 Pandemic Influenza Vaccine Safety Conference Atlanta, Georgia August 21, 2008.
Influenza Vaccine Surveillance System Pilot Project Pandemic Influenza Vaccine: Doses Administered and Safety Training Conference Atlanta, GA—Aug. 22,
National Health Information Privacy and Security Week Understanding the HIPAA Privacy and Security Rule.
Case Identification for the Missouri Perinatal Hepatitis B Prevention Program Libby Landrum, RN, MSN Viral Hepatitis Prevention Manager Bureau HIV, STD,
Communication Resources for Pandemic Influenza Planning Tanya Johnson, MPH Health Communications Specialist Contractor, Logistics Health Inc. Immunization.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
{ ADVERSE DRUG REACTIONS To ensure patient, family/caregiver and home health personnel are instructed to identify adverse reactions to medications and.
Management of Smallpox Vaccine Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention February 2003.
1 Antivirals in the Draft CDC Pandemic Plan David K. Shay Influenza Branch National Center for Infectious Diseases Centers for Disease Control and Prevention.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
1 VAERS Reporting During a Large Scale Vaccination Clinic in Chicago Lessons Learned Chicago Department of Public Health Immunization Program Lorraine.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
Capturing and Reporting Adverse Events in Clinical Research
Data and Information Management of the Smallpox Vaccine Program Department of Health and Human Services Centers for Disease Control and Prevention December.
Smallpox Vaccine Logistics: Distribution, Storage, and Security Department of Health and Human Services Centers for Disease Control and Prevention December.
John Naim, PhD Director Clinical Trials Research Unit
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Overview of Terrorism Research at the CDC Dixie E. Snider, M.D., MPH. Associate Director for Science Presented at 2003 Medical Research Summit March 6,
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
FDA/CBER Role in Smallpox Vaccine Safety Bob Ball, MD, MPH, ScM Chief, Vaccine Safety Branch Office of Biostatistics and Epidemiology CBER, FDA January.
Introduction to Developing a Vaccination Strategy for Smallpox Preparedness Department of Health and Human Services Centers for Disease Control and Prevention.
Tuberculosis Follow up Care PA Department of Health Role Maxine Kopiec Community Health Nursing Supervisor April 24, 2015.
Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.
Decision Support for Quality Improvement
National Smallpox Vaccination Update Joseph M. Henderson Centers for Disease Control and Prevention.
Smallpox Vaccination: Federal Activities Walter A. Orenstein, M.D. National Immunization Program Centers for Disease Control and Prevention.
Introduction to US Health Care
Epidemiology Tools and Methods Session 2, Part 1.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
POD 101 Introduction to Point of Dispensing Emergency Preparedness and Response Program & Community Health Services Version 1.1.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention February 2003.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
ADAPT serving geriatric populations in rural communities. Project ADAPT Assessing Depression and Proactive Treatment The Minnesota Area Geriatric Education.
The Value of Medication Therapy Management Services.
Topic 6 Understanding and managing clinical risk.
Risk Management, Assessment and Planning Committee III-4.
Local Public Health System Assessment using the NPHPSP Local Instrument Essential Service 6 Enforce Laws and Regulations that Protect Health and Ensure.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
1 DoD Smallpox Vaccination Program Policy – Training – Standards – Communication – Safety Assurance – Safety Assessment Science – Quality – Confidence.
Scottish Patient Safety Programme – Pharmacist Engagement Gordon Thomson Arlene Coulson Shadi Botros.
Smallpox Vaccine Program: Communications with the Public and Stakeholders Department of Health and Human Services Centers for Disease Control and Prevention.
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
Documentation, Registries and Performance Improvement Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious Diseases University of Louisville.
Saftey Agencies in Healthcare Practice OSHA CDCP CLIA FDA ISO WHO NIH USDHHS.
EBOLA GRANT WORK PLAN. Overview Region received: $258,238 Project Period: May 18, 2015-May 17, 2020 MN will call this EBP for Ebola Budget Period Requirements:
Introduction to US Health Care Unit 4 Chapter 14 Public Health Policy 14-1.
HIT FINAL EXAM REVIEW HI120.
Drug & Poison Control center
TIME CRITICAL DIAGNOSIS
Informational Webinar Today’s Webinar Objectives:  Describe the Role of the National Ebola Training and Education Center (NETEC)  Explore netec.org.
Immunization Safety System- Registry Linkages: Lessons Learned from the Smallpox Vaccination Program John Iskander, David Walker, Roseanne English-Bullard,
Health Facility Compliance Patient Quality Care Unit Division of Regulatory Services Texas Department of State Health Services.
Nelson Arboleda, MD, MPH Immunization Safety Office (ISO) Office of the Chief Science officer (OCSO/OD) Centers for Disease Control and Prevention (CDC)
CLINICAL TRIALS.

Clinical Trials — A Closer Look
Pharmacovigilance in clinical trials
This is an archived document.
Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events
Professional Organizations
Public Health Surveillance
Optum’s Role in Mycare Ohio
Smallpox Vaccinee Evaluation and Follow-Up
Presentation transcript:

Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002

Smallpox Vaccine Safety and Reporting Adverse Events Learning Objectives: – Describe the overall process for reporting clinically significant or unexpected adverse events (AEs) – Describe the roles and responsibilities of federal, state, and health care providers for AE monitoring and reporting

Smallpox Vaccine Safety and Reporting Adverse Events Learning Objectives: – Describe the purpose of the Vaccine Adverse Event Reporting System (VAERS) – List the steps for obtaining Vaccinia Immune Globulin (VIG) or cidofovir for treatment of AEs

Basic Overview of Smallpox Vaccine Adverse Events Reporting CDC State HD Clinic Individual Providers VAERS

Vaccine Adverse Event Reporting System (VAERS) National surveillance system administered by CDC and the Food and Drug Administration (FDA) Data analyzed to identify: – New or rare vaccine side effects – Increases in rates of known side effects – Associations with specific vaccine lots – Patient risk factors

Reporting Adverse Events Following Smallpox Vaccine What to report to VAERS – All clinically significant or unexpected AEs When to report – Clinically significant/unexpected AEs within 48 hours – Other AEs within 7 days

Reporting Adverse Events Following Smallpox Vaccine Who can report to VAERS – State Health Departments – Anyone How to report – – Fax: – Telephone: for form

CDC Roles and Responsibilities Tabulate AEs Determine the frequency of known serious AEs Monitor for unexpected AEs Conduct special studies of AEs Make VIG and Cidofovir available under Investigational New Drug (IND) protocol

CDC Roles and Responsibilities Provide technical assistance to state health departments to support safest possible use of smallpox vaccine Provide technical consultation to clinicians in diagnosis and management of adverse events after smallpox vaccination Work with FDA to monitor VAERS reports

State Health Department Roles and Responsibilities Develop a plan to assure monitoring of adverse events among public health smallpox response teams Identify an individual to oversee, establish, and coordinate vaccine safety monitoring

State Health Department Roles and Responsibilities Communicate with medical organizations Communicate with media on vaccine safety issues Inform medical providers about smallpox vaccination program

State Health Department Roles and Responsibilities Develop system for rapid reporting and assessment of AEs in vaccinees or their contacts: – Provide 24/7 coverage for answering questions – Ensure prompt reporting to CDC Clinically significant and unexpected AEs Vaccinia Immune Globulin (VIG) or Cidofovir requests Clinical outcome following treatment

State Health Department Roles and Responsibilities Develop system for rapid reporting and assessment of AEs in vaccinees or their contacts: – Contact CDC for VIG or Cidofovir requests – Ensure that patient VIG/Cidofovir IND paperwork is completed

Hospital Roles and Responsibilities Provide follow-up of vaccinees, including 24/7 coverage Perform vaccination site care Identify subspecialists to assist with assessment of suspected AEs

Hospital Roles and Responsibilities Promptly report clinically significant or unexpected AEs to state health departments Submit case report forms to state health departments

Vaccine Clinic Roles and Responsibilities Treat immediate AEs (i.e., anaphylaxis, syncope) Educate vaccinees on vaccination site care Ensure vaccinees have instructions for follow-up

Vaccine Clinic Roles and Responsibilities Know the reporting process for AEs Provide vaccinees with information on who to contact for suspected AEs Tabulate the number of persons vaccinated – Facilitates calculating ratio of AEs. – Use of the Pre-Event Vaccination System (PVS) software automatically tabulates the numbers

Individual Providers Roles and Responsibilities Recognize possible AEs Manage and treat AEs Refer patients as clinically indicated to an appropriate specialist

Individual Providers Roles and Responsibilities Report AEs to state health department Comply with IND protocol requirements if VIG and Cidofovir used for treatment of AEs Report AEs to VAERS

Obtaining VIG and Cidofovir Treating physician contacts designated state official State informs CDC of VIG and or Cidofovir request CDC releases VIG or Cidofovir

Summary CDC, the states, and individual health care providers and facilities all have important roles and responsibilities in the surveillance and reporting of clinically significant or unexpected AEs Clinically significant or unexpected AEs should be reported promptly to the state health department, which will in turn report to CDC Clinically significant or unexpected AEs should also be reported through VAERS

Summary CDC will monitor these reports and provide information to assist the states Some AEs will benefit from treatment with VIG or Cidofovir, which is available from CDC under an IND protocol

Summary Everyone’s participation in this process will be critical to ensure we learn as much as possible about smallpox in today’s world Information and resources for smallpox surveillance and reporting can be found at

For More Information CDC Smallpox website National Immunization Program website